Key result
Intensified immunosuppression controls recurrent post-transplant giant cell myocarditis but triggers disseminated Nocardia infection.
Why the study?
Although recurrent giant cell myocarditis after orthotopic heart transplant has been reported, the prognosis is not well understood and clear management guidelines are lacking.
Case Report (n=1)
No
Recurrent giant cell myocarditis after heart transplantation can be managed with intensified immunosuppression (pulse steroids, ATG, sirolimus), but requires careful multidisciplinary balancing due to life-threatening opportunistic infections such as disseminated Nocardia.
Answers are grounded in this paper and cite their sources.
Vigilant infection monitoring is essential during immunosuppression escalation for recurrent post-transplant giant cell myocarditis; leaves open optimal regimens.
Background Giant cell myocarditis (GCM) is a rare but well-known cause of fulminant myocarditis. Despite optimal medical therapy, many patients progress to orthotopic heart transplant (OHT). We present a case of recurrent GCM following OHT, including complex considerations in patient management and infectious sequelae. Case summary A 33-year-old previously healthy male presented with 2 months of worsening shortness of breath. Transthoracic echocardiogram (TTE) demonstrated a left ventricular ejection fraction of 30–35%. After ruling out an ischaemic aetiology, he was discharged on guideline-directed medical therapy and later presented with productive cough, worsening dyspnoea on exertion, and diarrhoea. He was found to have elevated troponins and N-terminal pro-brain natriuretic peptide, lactic acidosis, progression of severe bi-ventricular dysfunction on TTE and right heart catheterization, and low cardiac index (1.0 L/min/m2) requiring inotropes. He then required left ventricular assist device as a bridge to OHT. Pathology of the apical core diagnosed GCM as the cause of his fulminant heart failure. He eventually underwent heart transplantation, which was complicated by recurrent GCM. Treatment required intensification of his immunosuppressive regimen, which led to multiple infectious sequelae including norovirus, Shiga-like toxin producing Escherichia coli, and disseminated nocardia of the lung and brain. As of the most recent follow-up, the patient is currently clinically stable. Discussion Although recurrent GCM after OHT has been reported in the literature, the prognosis is not well understood and there are no clear guidelines regarding management. This case summarizes clinical considerations, treatment strategies, and adverse effects of recurrent GCM treatment.
No takes yet. Share an insight, caveat, or question.
Frankel et al. (2022) conducted a case report in Recurrent giant cell myocarditis following orthotopic heart transplantation (n=1). Intensified immunosuppression (pulse-dose corticosteroids, anti-thymocyte globulin, tacrolimus, mycophenolate, prednisone, and sirolimus) was evaluated on Resolution of recurrent giant cell myocarditis and clinical stability vs infectious complications. Intensified immunosuppression with pulse steroids, ATG, and sirolimus controlled 3 post-transplant giant cell myocarditis recurrences in a 33-year-old man but caused disseminated Nocardia.
Synapse has enriched 10 related papers. Consider them for comparative context: